Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
GlobeNewswire, Inc.
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass...
PyroGenesis Confirms Completion of Installation of 4.5 MW Plasma Torch System at U.S. Defense and Aeronautics Research Facility
GlobeNewswire, Inc.
MONTREAL, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to...
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
GlobeNewswire, Inc.
Baltimore, MD, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The signs of poor metabolic health can be difficult to analyze without a clinical framework.
Lantronix Secures Blue UAS Companion Computer SOM Listing, Expanding Defense Drone Opportunity
GlobeNewswire, Inc.
IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lantronix Inc. (Nasdaq: LTRX), a global provider of Edge AI and Industrial IoT solutions that power NDAA-compliant unmanned compute systems, critical infrastructure and resilient enterprise...
Nxera Announces Successful Resolution of miniG Patent Infringement Action
GlobeNewswire, Inc.
Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has entered into a settlement agreement...
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
GlobeNewswire, Inc.
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD,...
Taiwan Expo USA 2026 Concludes in Dallas, Generating US$96.5 Million in Potential Procurement Value and Deepening U.S.-Taiwan Industrial Partnership
GlobeNewswire, Inc.
A Media Snippet accompanying this announcement is available by clicking on this link.
Kleinschmidt Canada Welcomes Regan Willenborg as Project Engineer
EIN Presswire
Project Engineer brings 8 years of experience to support continued growth of Kleinschmidt Canada PETERBOROUGH, ONTARIO, CANADA, October 1, 2026 /EINPresswire.com/ -- Kleinschmidt Canada, an employee-owned consulting firm specializing in...
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
GlobeNewswire, Inc.
OCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage focused on the Company’s development strategy for Ampligen® (rintatolimod) in metastatic...
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
GlobeNewswire, Inc.
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants...
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
GlobeNewswire, Inc.
MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,...
Autonomize Introduces Autonomize Context AI™, the Missing Context Foundation That Makes AI Agents Grounded, Useful, and Scalable for Healthcare Enterprises
GlobeNewswire, Inc.
AUSTIN, Texas, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Autonomize announced the general availability of Autonomize Context AI™, a shared intelligence foundation that transforms fragmented enterprise knowledge into living context that healthcare AI...
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
GlobeNewswire, Inc.
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented,...
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
GlobeNewswire, Inc.
Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078),...
Clinical Trials Market Report Highlights Key Segments, Regional Trends And Major Competitors
EIN Presswire
The Business Research Company's Clinical Trials Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 1, 2026 /EINPresswire.com/ -- "The clinical trials sector has witnessed...
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
GlobeNewswire, Inc.
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where...
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire, Inc.
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Applied Materials and Besi Expand Strategic Partnership to Advance Next-Generation Packaging for AI Scaling
GlobeNewswire, Inc.
Besi joins Applied's EPIC Center as an Innovation Partner, extending a collaboration that began in 2020 with the companies' joint Hybrid Bonding Center of Excellence in Singapore Expanded collaboration targets next-generation 3D IC scaling, logic...
ViroMissile Completes First Dose Cohort of Phase I Trial of Intravenously-Dosed IDOV-2; Safety Review Committee Clears Advancement to Next Cohort
GlobeNewswire, Inc.
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the completion of the first dose cohort in its ongoing...
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
GlobeNewswire, Inc.
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study...
Sign up for:
Technology News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.